Enliven Therapeutics is a biopharmaceutical company in Boulder, CO, developing small molecule inhibitors for cancer treatment. Their lead products, ELVN-001 and ELVN-002, are in Phase 1 trials for chronic myeloid leukemia and solid tumors with HER2 alterations.